MedTrace Logo

Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors

NCT01740739 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2013-06-14

No results posted yet for this study

Summary

The objective of this study is to explore the relationship between the ClearView scan results and a variety of cardiovascular risk indicators such as the Coronary Calcium Score, Framingham Risk Factors, Reynolds Risk Score, and biomarkers of inflammation. The ClearView device is a bio-electrographic tool that may assist medical professionals in rapid assessment of the systemic origin of the patient's presenting symptom(s). The ClearView is a potentially valuable resource that may benefit a physician's office by offering expedited differentiation capabilities. The subsequent results have the potential to include more data that would allow rapid patient diagnosis, triage, and treatment; optimized precious resource expenditure (nursing, physician, etc.); lower costs to facility, patient and insurance company; and decreased office wait time.

Conditions

Sponsors & Collaborators

  • Mission Internal Medical Group

    collaborator UNKNOWN

  • Epic Research & Diagnostics, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael Miyamoto, MD · Mission Internal Medical Group

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-06-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01740739 on ClinicalTrials.gov